Xiromed launches generic Faslodex

Insud Pharmaceuticals’ Xiromed division is debuting fulvestrant injection 250 mg/5 ml (50 mg/ml), a generic of Faslodex.

Faslodex is used to treat advanced-stage, hormone receptor-positive, HER2-negative breast cancer. 

[Read more: Xiromed intros 2 generics]

Faslodex and its generics had a market value of $101.4 million for the 12 months ending July 2022, according to IQVIA.

“The launch of Fulvestrant injection demonstrates Xiromed’s ability to leverage Insud Pharmaceuticals’ breadth of manufacturing capabilities to bring high-quality, vertically integrated generic products to the U.S. market,” Rob Spina, CEO of Xiromed, said.

[Read more: Xiromed, Genzum unveil generic Naftin]

“ Our fulvestrant pre-filled syringe product is manufactured at Insud’s dedicated hormonal injectable facility, Laboratorios Farmalan, located in Leon, Spain, and the fulvestrant active pharmaceutical ingredient is manufactured at our API facility, Industriale Chimica in Saronno, Italy. Xiromed is committed to expanding our portfolio of hormonal injectable products.”